Using a genetically engineered murine model of NF2, we demonstrate that selective inhibition of COX-2 with celecoxib fails to prevent the spontaneous development of schwannomas or sensorineural hearing loss <i>in vivo</i>, despite elevated expression levels of COX-2 in <i>Nf2</i>-deficient tumor tissue.